Johnson & Johnson's anti–interleukin-23 therapy, guselkumab, has shown greater efficacy than AbbVie's Humira in a Phase II psoriasis trial – but can it compete in a saturated market place?
Johnson & Johnson's anti–interleukin-23 therapy, guselkumab, has shown greater efficacy than AbbVie's Humira in a Phase II psoriasis trial – but can it compete in a saturated market place?
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Abeona plans to offer an outcomes-based payment model for Zevaskyn, which likely will see complementary use with Krystal’s Vyjuvek in recessive dystrophic epidermolysis bullosa patients.
The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.
CEO Carlos Gallardo tells Scrip the Barcelona-based group has laid the foundations to advance four promising assets that have considerable potential for a variety of dermatological diseases.
Incyte’s JAK1 inhibitor meets the primary endpoint in two Phase III hidradenitis suppurativa trials, but the drug may not be able to supplant established biologic therapies.
Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.
The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.
Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.
